| Literature DB >> 10998549 |
P Bloms-Funke1, C Gillen, A J Schuettler, S Wnendt.
Abstract
The nociceptin/orphanin FQ (N/OFQ) receptor (e.g. the human ortholog ORL1) has been shown to be pharmacologically distinct from classic opioid receptors. Recently, we have identified buprenorphine as a full ORL1 agonist using a reporter gene assay. For further functional analysis, buprenorphine's effects on ORL1 receptors were investigated using a K(+) channel (GIRK1) assay in Xenopus oocytes and GTPgammaS assay in CHO-K1 membrane preparations. In both assays, buprenorphine behaved as a partial agonist compared to nociceptin itself. The N/OFQ agonism of buprenorphine might contribute to actions of buprenorphine in pain models in vivo beside its mu- or kappa-opioid receptor mediated effects.Entities:
Mesh：
Substances：
Year: 2000 PMID： 10998549 DOI： 10.1016/s0196-9781(00)00252-7
Source DB: PubMed Journal: Peptides ISSN： 0196-9781 Impact factor: 3.750